Compare · ARGX vs MGX
ARGX vs MGX
Side-by-side comparison of argenx SE (ARGX) and Metagenomi Therapeutics Inc. (MGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and MGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $50.12B, about 931.0x MGX ($53.8M).
- Over the past year, ARGX is up 29.5% and MGX is down 0.7% - ARGX leads by 30.1 points.
- ARGX has been more active in the news (8 items in the past 4 weeks vs 3 for MGX).
- ARGX has more recent analyst coverage (25 ratings vs 8 for MGX).
- Company
- argenx SE
- Metagenomi Therapeutics Inc.
- Price
- $806.62+1.44%
- $1.44+2.86%
- Market cap
- $50.12B
- $53.8M
- 1M return
- +5.36%
- +5.49%
- 1Y return
- +29.46%
- -0.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2024
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
- SEC Form 6-K filed by argenx SE
- argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
Latest MGX
- SEC Form DEFA14A filed by Metagenomi Therapeutics Inc.
- SEC Form DEF 14A filed by Metagenomi Therapeutics Inc.
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
- SEC Form 4 filed by Irish Jian
- SEC Form 4 filed by Wein Matthew
- SEC Form 4 filed by Wapnick Pamela
- Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
- Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
- Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
- SEC Form S-8 filed by Metagenomi Therapeutics Inc.